Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Cybin Inc N.CYBN

Alternate Symbol(s):  CYBN

Healthcare Drug Manufacturers - Specialty & Generic
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NEO:CYBN)

Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Business Wire 5 days ago

Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million

Business Wire March 19, 2024

Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas

Business Wire March 18, 2024

Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder

Business Wire March 15, 2024

Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

Business Wire March 14, 2024

Announces Oversubscribed Private Placement of U.S. $150 Million

Business Wire March 13, 2024

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Business Wire March 13, 2024

Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003

Business Wire March 12, 2024

Cybin to Present at the TD Cowen 44th Annual Health Care Conference

Business Wire February 27, 2024
View More News ››

Opinion & Analysis (NEO:CYBN)

A Company on a Mission to Revolutionize Mental Healthcare. Here’s How.

Dave Jackson February 1, 2022

The Psychedelic Opportunity You Need to Know About

Dave Jackson October 20, 2021

Revolutionizing Mental Health Treatment

Featured Submission August 16, 2021

A New Frontier in Psychedelic Therapeutics

Featured Submission January 12, 2021

A Psychedelic & Nutraceutical Opportunity: A Boost for the Brain and Your Portfolio

Dave Jackson September 22, 2020
View More Opinion ››

Bullboard Posts (NEO:CYBN)

Globe says MindMed, Cybin get nod from U.S. FDA

2024-04-08 07:12 ET - In the News See In the News (C-MMED) Mind Medicine (MindMed) Inc (2) The Globe and Mail reports in its...
Tardis - 7 days ago

Very Smart Money Bought In

Buy on any weakness IMO. This sector is and will continue to recieve serious attention. Cybin will be the belle of the ball IMHO...
Tardis - March 19, 2024

Cybin To Present

  Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas  ...
Tardis - March 18, 2024

Phase 2 Proof Of Concept

https://ir.cybin.com/investors/news/news-details/2024/Cybin-Initiates-Phase-2-Proof-of-Concept-Study-of-CYB004-in-Generalized-Anxiety...
Tardis - March 15, 2024

CYBIN CEO Doug Drysdale Interview

https://www.youtube.com/watch?v=qZWGF2M4vwE Tight Lines Gilly
Tardis - March 14, 2024

News - Positive end of phase 2

https://ir.cybin.com/investors/news/news-details/2024/Cybin-Announces-Positive-End-of-Phase-2-Meeting-with-FDA-for-CYB003-in-Major...
Tardis - March 14, 2024
View more Bullboard ››

LNG Energy Group Corp.

LNG Energy Group Corp.

LNG Energy Group Corp is a Canada-based company, which is focused on the acquisition and development of natural gas ...
View More »